As per the attached file
Awaiting price reaction for this filing.
Sellwin Traders' board, meeting on 31st July 2025, approved raising the Authorised Share Capital from Rs. 50 crore to Rs. 58.40 crore, subject to shareholder approval via postal ballot. The board also approved a preferential issue of up to 4.75 crore convertible warrants at a minimum price of Rs. 8.40 per warrant (including premium), with each warrant convertible into one equity share of Rs. 2 face value within 18 months of allotment. Warrants are proposed to be allotted to 103 allottees (mostly individuals and one entity — Mideast Healthcare Pvt Ltd getting the largest tranche of 40 lakh warrants), with 25% payable upfront and the balance 75% on conversion. If warrants are not exercised within 18 months, they lapse and the upfront amount is forfeited. A scrutinizer has been appointed for the postal ballot e-voting process.
This is a potential equity dilution event — if all 4.75 crore warrants are converted, the share count could expand materially, which may weigh on existing shareholders. On the positive side, the company could raise up to roughly Rs. 40 crore to fund growth, subject to shareholder approval.